Prevention of Vascular Dysfunction after Preeclampsia: A Potential Long-Term Outcome Measure and an Emerging Goal for Treatment by Lazdam, Merzaka et al.
Hindawi Publishing Corporation
Journal of Pregnancy
Volume 2012, Article ID 704146, 8 pages
doi:10.1155/2012/704146
Review Article
Prevention of Vascular Dysfunctionafter Preeclampsia:
A Potential Long-Term Outcome Measure and an Emerging Goal
for Treatment
Merzaka Lazdam,1 Esther F.Davis,1 Adam J. Lewandowski,1 Stephanie A. Worton,2
Yvonne Kenworthy,1 Brenda Kelly,2 andPaul Leeson1
1Department of Cardiovascular Medicine, Oxford Cardiovascular Clinical Research Facility, University of Oxford,
John RadcliﬀeH o s p i t a l ,O x f o r dO X 39 D U ,U K
2Department of Obstetrics and Gynaecology, University of Oxford, John RadcliﬀeH o s p i t a l ,O x f o r dO X 39 D U ,U K
Correspondence should be addressed to Paul Leeson, paul.leeson@cardiov.ox.ac.uk
Received 29 July 2011; Accepted 15 September 2011
Academic Editor: Christos Iavazzo
Copyright © 2012 Merzaka Lazdam et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Preeclampsia is increasingly being recognised as more than an isolated disease of pregnancy. In particular, preeclampsia
has emerged as an independent risk factor for maternal cardiovascular disease and has recently been recognised as a risk
factor for cardiovascular disease in children exposed in utero. Preeclampsia and cardiovascular disease may share important
pathophysiological and molecular mechanisms and further investigation into these is likely to oﬀer insight into the origins of
both conditions. This paper considers the links between cardiovascular disease and preeclampsia and the implication of these
ﬁndings for reﬁnement of the management of patients whose care is complicated by preeclampsia.
1.Introduction
Although traditionally preeclampsia has been viewed as a
condition that resolves completely with the delivery of the
placenta, there is now increasing evidence that preeclampsia
may constitute a condition with signiﬁcant long-term health
implications for both the mother and child. In particular
preeclampsia has recently emerged as an independent risk
factor for maternal cardiovascular disease 10–15 years after
the index pregnancy [1–3]. A history of preeclampsia is
therefore now considered a relevant factor in the cardiovas-
cular risk assessment in women [4] and is associated with
an increase in risk similar in magnitude to a history of
dyslipidemia [5]. Meta-analysis has demonstrated that in the
10–15yearsfollowingapreeclampticpregnancywomenhave
an increased risk of developing hypertension (RR 3.7 95%
C.I. (2.7–5.05, P<0.001)), coronary artery disease (RR 2.16
95% C.I. (1.86–2.52, P = 0.001)), and stroke (RR 1.81 95%
C.I. (1.45–2.27, P = 0.00) [1]. Additionally, it has been
demonstrated that there is a graded relationship between
the risk of cardiac disease and the severity of preeclampsia
with maternal risk being greatest with early onset or severe
preeclampsia [6]. Children born to preeclamptic women
have also been demonstrated to have elevated blood pressure
in childhood and adolescence [7–12].
This highlights potentially important pathophysiological
or molecular links between preeclampsia and cardiovascular
disease. Greater insight into these links may identify new
opportunities to understand disease predisposition and
treatment and may also raise the possibility that prevention
of vascular dysfunction should be an important long-term
goal of preeclampsia management. This paper will consider
the current literature considering the links between cardio-
vascular disease and preeclampsia and the implication of
theseﬁndingsforreﬁningthemanagementofpatientswhose
care is complicated by preeclampsia.2 Journal of Pregnancy
2.What LinksPreeclampsiaand
CardiovascularDisease?
The aetiology of preeclampsia remains incompletely under-
stood, though disturbed placentation and placental func-
tioning in early pregnancy remains the leading hypothesis
[31]. During normal placental development, fetal cytotro-
phoblasts invade the maternal spiral arteries transforming
them to high-caliber capacitance vessels providing low resis-
tance placental perfusion adequate to sustain fetal growth
[32]. However, inadequate spiral artery remodeling in pree-
clampsia is thought to lead to chronic placental ischaemia
or intermittent ﬂow through the narrow muscular arteries
thereby creating an ischaemia-reperfusion phenomenon
[33].
Reactive oxygen species and cytokines released from the
ischaemicplacentatriggerasystemico xidativestress[34]and
contribute to the exaggerated systemic inﬂammatory reac-
tioninpreeclampsia[33,35].Syncytiotrophoblastsundergo-
ing apoptosis also shed increased numbers of microparticles
in the maternal circulation which contribute to this process.
The release of cytokines and acute phase proteins, such as
TNFα, leptin, and PAI-1, not only enhance the inﬂammatory
response but also induce some of the observed metabolic
disturbances in preeclampsia including insulin resistance,
lipolysis, and hyperlipidaemia [33, 34].
Furthermore, hypoxic oxidative stress and inﬂammatory
stimuli provoke the release of antiangiogenic factors (via
NF-κB pathways) [33, 36–38]. Soluble Fms-Like Tyrosine
kinase-1 (sFLT-1), a circulating truncated form of VEGF
receptor, binds and reduces levels of VEGF and PlGF in
the maternal circulation thereby inhibiting angiogenesis and
vasodilatation [39]. This aberrant vasculature is thought
to lead to a cascade of events which end in symptomatic
systemic endothelial dysfunction [40]. Soluble endoglin, a
TGF-β coreceptor, is one of the antiangiogenic factors that
enhancesvascularpermeabilityandmaypossiblyaﬀectnitric
oxide synthesis and vasodilatation via altered downstream
signallingintheTGF-βpathwaycontributingtotheendothe-
lial dysfunction [35]( Figure 1).
Consistent with these biological changes, reduced endo-
thelial-dependent vasodilatation in conduit and resistance
arteries [21, 41–47] has been demonstrated in women who
have preeclampsia. They also appear to have increased
arterial stiﬀness [13], increased atherosclerosis [48], and
diminished capillary density [49]. Biochemical markers of
endothelial activation and dysfunction are also elevated in
preeclampsia [34, 50]. Maternal endothelial dysfunction is
also present in conduit vessels before the onset of clinical
disease [42] and up to three years after an aﬀected pregnancy
[24, 51, 52]. The increase in cardiovascular risk following
preeclampsia may be a consequence of the pro-atherogenic
impact of persistent endothelial dysfunction, a result of
subclinical endothelial injury at the time of pregnancy,
or to preexisting diﬀerences in endothelial function that
predispose to both conditions (Figure 2).
Dysfunction of the vascular endothelium is a key factor
in the development of atherosclerotic cardiovascular disease
and has been demonstrated to precede clinically identiﬁable
structural changes in the vasculature [53]. Peripheral dys-
function of the vascularendothelium has been demonstrated
to correlate with increased risk of clinical events [54]a n d
all cause mortality [55] and associates with many traditional
cardiovascular risk factors including hypertension, diabetes
mellitus,insulinresistance,hypercholesterolemia,andsmok-
ing[56].Inadditiontothis,endothelialdysfunctionhasbeen
demonstrated in young adults predisposed to hypertension
without clinical evidence of arterial disease [57]. Endothelial
health and nitric oxide synthase activity are crucial in
modulating arterial distensibility [58–60] and carotid intima
media thickness [61, 62] independent of risk factors [62]a s
well as myocardial hypertrophic responses in animals [63–
65]. Left ventricular mass, another powerful independent
predictor of mortality and morbidity in adults free of clinical
disease [66], has a graded relationship with vascular endo-
thelial vasomotor responses in hypertensive adults [67–72].
Thestrongrelationshipbetweenendothelialdysfunctionand
cardiovascular outcomes and risk factors make it an in-
teresting pathophysiological endpoint in the evaluation of
therapies designed to modify long-term cardiovascular risk.
3. MaternalVascular Functionas
anIntermediateEndpointin
the Management of Preeclampsia
As women who have experienced preeclampsia constitute a
relatively young group, and there is potentially a prolonged
period between exposure and clinical outcome, intermediate
measureswhichmayindicateapotentiallymodiﬁablechange
in risk are of particular value. Noninvasive measures of
v a s c u l a rf u n c t i o na r ew i d e l yu s e da ss u r r o g a t em a r k e r so f
cardiovascular risk [73, 74]. For example, increasing arterial
stiﬀness, demonstrated by an increase in pulse wave velocity,
is an antecedent factor in elevated blood pressure, predicts
the future cardiovascular risk of adults, and correlates
strongly with the presence of atherosclerosis [75]. Similarly,
early evidence of atherosclerosis demonstrated by increased
thickness of the arterial wall is correlated with coronary
arterydiseaseandispredictiveoffutureinfarctionandstroke
[75, 76]. Changes in these parameters may therefore also
oﬀer unique insight into the cardiovascular risk of women
and children following a preeclamptic pregnancy.
Several relatively small-scale studies have also demon-
strated vascular dysfunction after pregnancy complicated by
preeclampsia with evidence of endothelial dysfunction in the
macrocirculation [14, 16, 18, 22–24, 26] up to a median of
3 years and the microcirculation up to 25 years later [15, 27,
30],aswellasincreasedarterialstiﬀness[13,14,16,17]upt o
almost 5 years after the index pregnancy and atherosclerosis
over 3 months postpartum [19]. Elevation of systemic
biomarkers of endothelial injury and inﬂammation have also
been described between 6 weeks [77]a n d2 0y e a r s[ 78–80]
following preeclampsia. The characteristics and results of
current literature considering the impact of preeclampsia on
vascular structure and function are summarised in Table 1.
Thereis,however,somedisparityinresultswithsomestudies
demonstrating no change in vascular function followingJournal of Pregnancy 3
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↑ Oxidative stress
↑ Antiangiogenic factors ↓ Proangiogenic factors
sFlt-1
sEng
VEGF
PlGF
↑ Lipid peroxides
↑ ROS
↑ NF-κB
↑ Superoxide
Endothelial dysfunction
↑ Syncytiotrophoblast
microparticles
Maternal
factors
(genetic and
environmental)
↑ Systemic inﬂammatory
reaction
Hypercoagulopathy
TNFα
IL6
IL8
↑ TF
↓ Prot C
↑ vWF
Placental ischaemia
Figure 1: Molecular and vascular mechanisms of endothelial dysfunction in preeclampsia. Defective placentation, a common feature of
preeclampsia, triggers a cascade of events including oxidative stress and exaggerated inﬂammatory reaction and angiogenic imbalance which
exacerbate endothelial dysfunction. Impaired endothelial function plays a central role in the clinical manifestations of preeclampsia such as
hypertension and proteinuria.
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Figure 2: Theoretical timelines of impairment of endothelial function and development of cardiovascular disease following preeclamptic
pregnancy. (1) In the normal individuals there is a gradual age-related reduction in endothelial function, which can be exacerbated by the
presence of cardiovascular risk factors and associates with the future risk of clinical cardiovascular disease. (2) Women who experience
preeclamptic pregnancies are known to have impaired endothelial function during pregnancy and up to 3 years following an aﬀected
pregnancy. It is possible that these women begin life with normal endothelial function, which is acutely impaired during a preeclamptic
pregnancy. This followed by ongoing age-related decreases in endothelial function may relate to the increased incidence of cardiovascular
disease in these individuals. (3) Alternatively, women who develop preeclampsia may have primary endothelial dysfunction which both puts
them at risk of preeclampsia, this may then be exacerbated by the preeclamptic pregnancy (solid line), or simply persist (dotted line), in
either case leading to higher incidence of cardiovascular disease.
preeclampsia [21, 25, 28, 81]. This may in part reﬂect
heterogeneity in patient cohorts, severity of preeclampsia,
size of cohorts, the timing of the studies following the
aﬀected pregnancy, as well as diﬀerences in the vascular
beds studied and the techniques employed. In the future
more detailed long-term follow-up studies of such women
may clarify changes in cardiovascular physiology and inform
future treatment.
4. Offspring VascularFunction
FollowingPreeclampsia
Even more than their mothers, children born following a
preeclamptic pregnancy, constitute a cohort where early
life preventative strategies may have a profound impact
on future cardiovascular risk. Furthermore, adults whose
mothers had preeclampsia themselves have a higher riskJournal of Pregnancy 5
of the condition. Therefore, in this group evidence of
subtle changes in vascular physiology indicating changes in
risk are of particular importance. The body of literature
considering cardiovascular outcomes in the oﬀspring of
preeclamptic pregnancies is sparse when compared to that
considering maternal health. A single 60-year-follow-up
study of individuals born to preeclamptic women demon-
strated an increased risk of stroke in later life (RR 1.9 95%
C.I. (1.2–3.0, P = 0.01)) [82]. Oﬀspring of hypertensive
pregnancies have also been shown to have an increased risk
of hypertension as adults [82, 83] as well as having increased,
although not pathological, blood pressure in childhood and
adolescence [84]. Meta-analysis suggests that the magnitude
of this increase in young individuals for systolic blood
pressure is 2.3mmHg and for diastolic blood pressure is
1.7mmHg [84]. Although such increases are unlikely to be
clinically recognisable, it may have signiﬁcant public health
signiﬁcance as a 2mmHg rise in systolic blood pressure has
beenassociatedwitha7% increasein ischaemicheartdisease
mortality and a 10% increase in stroke [85].
Pretermoﬀspringborntohypertensivepregnanciesdem-
onstrate a distinct cardiovascular phenotype, characterised
byreducedconduitarteryendothelialfunctionandincreased
evidence of early atherosclerosis, compared to individuals
born preterm to normotensive women [7]. A ﬁnding which
has now been replicated in other groups [27, 86, 87]a n dm a y
be similar to the vascular dysfunction seen in women follow-
ing preeclamptic pregnancies [27]. Although the underlying
mechanisms remain unknown, there is substantial evidence
of “programming” of aspects of vascular biology during
fetal development, in particular en-dothelial responses
[88] and arterial stiﬀness [89]. The risk to the oﬀspring is
likely to be mediated through changes in maternal blood
pressure, vascular resistance in the placenta, or exposure
to maternal factors (such as antiangiogenic factors [90],
vasoactive substances [91] ,a n dr e a c t i v eo x y g e ns p e c i e s )
in the fetomaternal circulation. Optimal management of
preeclampsia may have indirect beneﬁts to reduce cardio-
vascular risk in the oﬀspring of such pregnancies [92].
Hence, better understanding of the long-term vascular
changes in oﬀspring of preeclampsia may allow assessment
of novel and previously unrecognised long-term outcomes
of preeclampsia with important public health signiﬁcance.
5. Conclusions andFutureDirections
It is now becoming clear that preeclampsia is more than
an isolated disease of pregnancy. The long-term health
implications of this condition for both the women and their
children are increasingly being recognised and incorporated
into clinical risk assessments [4]. Both women and chil-
dren exposed to preeclampsia exhibit an adverse vascular
phenotype, a propensity to subclinical atherosclerosis, and
increasedriskofadversecardiacandvasculareventsinfuture
life. As preeclampsia aﬀects 2–5% of the population this
altered risk is relevant to the health of 1.2 to 3 million people
in the UK and 6 to 15 million people in the USA. Optimal
management of preeclampsia may be able to improve
short and long-term vascular outcomes in these individuals.
W h i l ew er e m a i nu n a b l et oe ﬀectively prevent preeclampsia
attempts to reduce its long-term impact on those exposed
are of potential importance. Future studies that deﬁne
the detailed cardiovascular phenotype of those exposed to
preeclampsia may allow identiﬁcation of potential targets
for future preventative strategies. Furthermore, studies into
the mechanisms underlying the altered cardiovascular phe-
notype may provide unique insight into pathophysiological
or molecular links between preeclampsia and cardiovascular
disease, which may direct us to novel treatment strategies
for both conditions. Vascular dysfunction is an early marker
of cardiovascular risk, correlating with future risk of car-
diac events and preceding structural vascular change [53].
Improvement in vascular function would therefore be a
valuable intermediate endpoint in studies aiming to reduce
risk in this potentially young and generally asymptomatic
population before the onset of clinical disease.
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